US fund Platinum acquires Inventia Health in India foray

Platinum Equity makes its debut in India by acquiring a majority stake in Mumbai's Inventia Healthcare. With a valuation of Rs 2,500 crore, the deal sees PE investors exiting while the promoter retains a minority stake. Platinum Equity, managing over $48 billion in assets, is well-known for its expertise in the healthcare sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZldEqhQ
via IFTTT

Read More

India's healthcare in critical condition: 4 out of 5 public health centers below par, reveals new Govt report

A recent Indian government self-assessment reveals that most public health facilities, including district hospitals and primary centers, fall short of essential standards. Only 20% meet benchmarks for infrastructure and resources, with 42% scoring below 50%. Initiatives aim to bring 70,000 facilities to standard within 100 days, backed by inspections and funding under the National Health Mission. This highlights urgent reforms needed to enhance healthcare nationwide, promising better services and equity in healthcare delivery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Sge160z
via IFTTT

Read More

HCG acquires Vizag based cancer hospital for enterprise valuation of Rs 414 crore

HCG, India's leading cancer care chain, acquired a majority stake in Visakhapatnam's Mahatma Gandhi Cancer Hospital for Rs 414 crore. The deal begins with a 51% ownership, aiming to complete 85% in 18 months. The hospital's FY24 revenue was Rs 120.2 crore with an EBITDA of Rs 42.2 crore, expected to boost HCG's annual EBITDA by Rs 3 per share and consolidate its position in the Vizag region.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JdwW6tB
via IFTTT

Read More

India to make drugs for diabetes, obesity under PLI by 2026, says report

The Indian government plans to introduce a production-linked incentive (PLI) program in 2026 to boost domestic manufacturing of GLP-1 drugs, used for treating diabetes and obesity. The anti-obesity medication market is projected to reach $100 billion by 2030, as per Goldman Sachs Research. Major Indian pharmaceutical companies like Sun Pharmaceutical Industries Ltd., Cipla Ltd., and Dr. Reddy’s Laboratories Ltd. are developing weight-loss formulations and generic drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZEV8iPJ
via IFTTT

Read More

Why self-medicating without consulting a dermatologist is a bad idea

The pursuit of flawless skin through unguided skincare practices, influenced by social media and beauty trends, can result in adverse reactions. Seeking professional advice before experimenting with potent products is crucial to prevent skin damage and maintain skin health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FG4xpLY
via IFTTT

Read More

Risk-based audits of drug units to begin from July 1

The revised Schedule M, which is considered more stringent than the World Health Organization's (WHO) good manufacturing practices (GMP) in certain areas, was notified on December 28, 2023. Companies with turnover of over ₹250 crore will have to comply with the upgraded version of Schedule M, starting July 1, and the remaining others, which are largely micro, small, and medium enterprises (MSMEs), have been given a year's time to comply. Inspections on those firms will begin from January 1, 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/erNkOYW
via IFTTT

Read More

WHO warns alarming levels of physical inactivity among Indians, says women more physically inactive than men

A study in The Lancet Global Health highlights that nearly 50% of Indian adults are physically inactive, posing severe health risks. The study shows a significant rise in inactivity from 2000 to 2022, with women being more affected than men. City doctors attribute this to sedentary office work and poor diets. The lack of physical activity increases the risk of cardiovascular diseases, cancers, and psychological issues. Experts stress the need for regular exercise and healthier lifestyles to address this growing concern.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OerSyTk
via IFTTT

Read More

India pharma units fare better in US checks in 2023

The drug regulator United States Food and Drug Administration (USFDA) has classified 13%, or 19 out of 145 inspections it carried out against Indian facilities, as Official Action Indication (OAI) in 2023, which is lower than the global average of 15% OAIs, according to a report by Indian Pharmaceutical Alliance and McKinsey & Company said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/12gmDGe
via IFTTT

Read More

Norms soon on disposing of expired medicines

The document is in the final stages of completion. It will include procedures to be followed for disposal, collection, storage and transportation of expired and unused drugs. Improper disposal of medications that have crossed the expiry date mentioned on the label or not used by the individual for whom they were prescribed and purchased may be hazardous to public health, animal health and environment, officials said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Cuqz56X
via IFTTT

Read More

Dr Reddy's to buy nicotine replacement brands from UK-based Haleon for $632 million

The portfolio to be acquired consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product – Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uspxoX4
via IFTTT

Read More

Diabetes management made easier: Your guide to a healthier lifestyle

Proactively collaborating with healthcare professionals for personalized strategies enhances diabetes management, leading to improved overall well-being and better health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QmS8bNl
via IFTTT

Read More

World's first epilepsy device fitted in 13 year old UK boy's skull; Here's how the device works

Oran Knowlson, a 13-year-old from England with severe epilepsy, has become the first person to trial a new device implanted in his skull to control seizures. The groundbreaking surgery, which took place at Great Ormond Street Hospital in London, has reduced Oran's seizures by 80%. The device, a Picostim neurotransmitter, aims to disrupt abnormal brain signals causing epilepsy. Oran's improved quality of life following the surgery has brought hope to others with treatment-resistant epilepsy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XLSewzD
via IFTTT

Read More

US lawmakers questions FDAs drug inspection programme in India and China

Three top American lawmakers have raised concerns about the FDA's foreign drug inspection program in India and China. In a letter to FDA Commissioner Robert Califf, they highlighted inconsistencies in inspection outcomes from January 2014 to April 2024. Some inspectors reported no compliance issues in numerous inspections, while others found issues in almost every inspection. The lawmakers, Cathy McMorris Rodgers, Brett Guthrie, and Morgan Griffith, pointed out these discrepancies and called for an investigation into the skill and thoroughness of FDA inspectors to ensure rigorous and consistent inspections.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kzTDcsP
via IFTTT

Read More

Everstone to merge two healthcare companies, list combined firm

Everstone Capital, a Pan Asia private equity fund, is merging Translumina Therapeutics, a major cardiac stent maker in India, as part of a big-ticket IPO plan.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pChraOv
via IFTTT

Read More

High costs of orphan drugs: Patients pay the price for policy hurdles in India

India manufactures APIs for over 400 FDA-approved orphan drugs, but patients face high costs due to Indian pharma companies' reluctance to develop these drugs domestically.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yp4mG8g
via IFTTT

Read More

Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant

Biocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patients' needs in Europe for treating cancer. The Bengaluru facility was also approved for biosimilar Trastuzumab manufacturing. EMA renewed GMP certificates for Biocon's facilities in Bengaluru and Malaysia. USFDA issued four observations after inspecting Biocon's Andhra Pradesh plant, concluding inspections on June 21, 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kCQXjyf
via IFTTT

Read More

Govt widens composition of drug, medical devices pricing reforms panel

The government has expanded a committee to look into pricing reforms for drugs and medical devices, including civil rights activists like All India Drug Action Network (AIDAN), Patient Safety and Access Initiative of India Foundation, and Medecins Sans Frontieres (MSF). The committee will evaluate availability and pricing of essential medicines, incentivize industry growth and exports, and consider a new Drug (Prices Control) Order (DPCO) as the current one is over a decade old.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Lz9RKQy
via IFTTT

Read More

Taller, stronger, sharper: Desi pharma is on a roll

India has witnessed a significant growth in pharmaceutical generic brands with sales over ₹100 crore in the last 15 years. These brands now make up 44% of the domestic formulation market valued at around ₹2 lakh crore. A report by investment banking firm Avendus Capital highlights the exponential increase in brands with sales exceeding ₹100 crore, reaching 388 in FY24 from 21 in FY09. These brands, including some with sales above ₹500 crore, have outpaced the industry growth rate, attributed to factors like lifestyle diseases and quality issues driving reliance on trusted brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z5r9btV
via IFTTT

Read More

Lupin, Eugia recall products from US market: USFDA

Drugmakers Lupin and Aurobindo Pharma are recalling products from the American market due to manufacturing issues, as reported by the US Food and Drug Administration (USFDA). Lupin Pharmaceuticals Inc, a US-based unit of Lupin, is specifically recalling 3,552 bottles of Cefixime for Oral Suspension (USP 200 mg/5 mL) because of "failed content uniformity specifications."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QTjBwcV
via IFTTT

Read More

Biocon gets 4 observations from USFDA for Andhra Pradesh facility

Biocon received four observations from the US health regulator after a GMP inspection at its API facility in Andhra Pradesh.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GLMAsV2
via IFTTT

Read More

Sun Pharma, Cipla enter licensing agreement with Takeda to market novel gastrointestinal drug in India

Sun Pharma and Cipla have entered a licensing deal with Takeda Pharmaceutical to commercialize Vonoprazan tablets in India. This novel drug, used to treat Gastroesophageal Reflux Disease (GERD) and related acid disorders, will be marketed by Sun Pharma as Voltapraz and by Cipla under their own brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZnMT0JL
via IFTTT

Read More

Sun Pharma inks pact with Takeda to introduce gastrointestinal drug in India

Sun Pharmaceutical Industries announced a licensing deal with Takeda Pharmaceutical to market Vonoprazan, a novel gastrointestinal drug, in India. The agreement allows Sun Pharma to commercialize 10 mg and 20 mg tablets of Vonoprazan, an innovative treatment for acid peptic disorders, under a non-exclusive patent license.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/X84RfQ2
via IFTTT

Read More

Look-alike, sounding similar drugs likely to face strict action

Earlier, in January India's Drug Technical Advisory Board (DTAB), India's apex drug advisory body, deliberated on the issue of same brand name (including look-alike and sound-alike ones) for different category of products and it suggested that to ensure patient safety, the manufacturing and marketing of different drugs with same brand name should "not be allowed."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FsGi9Vb
via IFTTT

Read More

Biocon seeks partner to test generic Wegovy, Ozempic in China

India's Biocon is seeking a Chinese partner to conduct clinical trials on generic versions of Novo Nordisk's popular diabetes drug Ozempic and weight loss treatment Wegovy. Biocon aims to eventually launch these generics globally, with plans to find a partner for the trials on over 500 patients in China, citing the substantial investment required. The move comes ahead of the patent protection expiry on key ingredients in the drugs in 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/B2Nn8Ay
via IFTTT

Read More

Emcure Pharmaceuticals receives SEBI nod for its IPO launch

Emcure Pharmaceuticals received SEBI nod for IPO launch after filing DRHP in December 2023. The IPO includes equity shares and an Offer of Sale by promoters. Proceeds will be used for debt payment. Emcure Pharmaceuticals is renowned for its global marketing of pharmaceutical products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/64XkCq5
via IFTTT

Read More

Delivery boxes unhealthy: Nutritionist calls out Swiggy and Zomato over plastic containers; Zomato CEO responds

Celebrity nutritionist Luke Coutinho recently called on food delivery platforms Swiggy and Zomato to switch to biodegradable, non-plastic containers for food packaging. Highlighting the health risks of using plastic, especially for hot foods, Coutinho's appeal emphasized the need for safer food delivery practices. Zomato CEO Deepinder Goyal responded positively, promising to highlight restaurants that use food-safe packaging, while Swiggy is yet to respond.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AaqlwHG
via IFTTT

Read More

Ozempic frenzy lures rich Indians to brave the gray market

People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage, fueling a high demand. According to Goldman Sachs Research, the anti-obesity medication market could hit $100 billion by 2030. In contrast, Indians have largely been observers in this global frenzy over the new weight-loss solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NEIAemn
via IFTTT

Read More

Expert panel to soon weigh plan to use generics for prescription drugs

An expert committee is set to discuss the feasibility of allowing generic substitutions for prescription drugs in India. The proposal has sparked a disagreement between the Indian Pharmaceutical Alliance (IPA) and the All India Drug Action Network (AIDAN). The IPA opposes the idea, arguing that it would lead to a surge of demand from trade channels, such as general pharmacy stores, which would not benefit patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NnEyFvX
via IFTTT

Read More

Cipla makes additional investment in German mRNA biotech

Ethris' has four potential drugs under development pipeline, of which one is for treating uncontrolled asthma and three other for primary ciliary dyskinesia - a rare yet chronic respiratory disease. During the COVID19 pandemic, mRNA vaccines gained importance due to the first regulatory approvals for SARS-CoV-2. mRNA-based medicines have a huge potential in several indications as infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VNR0enH
via IFTTT

Read More

Alembic Pharma gets USFDA nod for Dabigatran Etexilate capsules

Alembic Pharmaceuticals Ltd received final approval from the US health regulator for generic Dabigatran Etexilate capsules 75 mg and 150 mg to reduce stroke and blood clots in adults with a specific medical condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9PYGBh2
via IFTTT

Read More

Lupin enters CDMO business, names Abdelaziz Toumi as CEO of new subsidiary

Lupin, a pharmaceutical company, has launched a new subsidiary named Lupin Manufacturing Solutions (LMS) to enter the Contract Development and Manufacturing Organization (CDMO) business. Abdelaziz Toumi (Abdel), with extensive experience in biotech, pharma, and CDMO sectors across multiple continents, has been appointed as the CEO of LMS.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wCpfKX2
via IFTTT

Read More

Lupin appoints Abdelaziz Toumi as CEO of newly formed arm

Lupin Ltd appointed Abdelaziz Toumi as CEO of its new subsidiary, Lupin Manufacturing Solutions (LMS). Toumi, with over 20 years in biotech, pharma, and CDMO sectors, has held roles at Bayer, Merck, and Lonza. Based in Switzerland, he will also focus on India. LMS specializes in APIs and CDMO services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tIDxb3P
via IFTTT

Read More

Jaypee Healthcare admitted for corporate insolvency process

Fortis Healthcare, Apollo Hospitals, Medanta, and Max Healthcare are among companies interested in acquiring Jaypee Healthcare, a subsidiary of Jaypee Infratech in Noida with a total debt of about ₹1,000 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/R6gMojc
via IFTTT

Read More

Health Ministry issues interdepartmental referral guidelines for hospitals

The guidelines stress the need for a multi-disciplinary approach for patients with multiple co-morbidities and highlight the importance of training in high-quality patient care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NywjtfX
via IFTTT

Read More

Bharat Bio's Rotavirus vaccine Rotovac may be unsafe for children: Study

A study found that Bharat Biotech's Rotovac vaccine used in the government's immunization program increases the risk of intussusception in infants, a condition where the intestine telescopes into itself, leading to potential serious consequences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wybnF3V
via IFTTT

Read More

Sun Pharma-Moebius Medical anti-osteoarthritis injection shows sustained pain relief in clinical trials

Sun Pharma and Moebius Medical announced that their intra-articular injection MM-II showed greater pain relief than placebo for up to 26 weeks in osteoarthritis (OA) patients, based on clinical trial data. The study demonstrated that from weeks 12 to 26, more patients on MM-II experienced significant pain improvement compared to those on placebo. MM-II, a novel non-opioid, uses a proprietary suspension of liposomes to reduce joint friction and pain. The companies plan to initiate a Phase 3 clinical program and seek a CE Mark for the product in the European Union.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vO8qMTu
via IFTTT

Read More

Govt allows global tenders to access 120 key, patented drugs

In what could ease access to some patented medicines, the government has allowed global tenders to be floated for procurement of 120 drugs, including anti-diabetic medication Semaglutide, after the health ministry raised concerns over lack of domestic options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CQvOPRa
via IFTTT

Read More

City dwellers rely more on Ayush than rural folk, says govt data

The results of the first nationwide study done on Ayurveda, Yoga & Naturopathy, Unani, Siddha, Sowa Rigpa and Homoeopathy found that 52.9% of the people in urban areas used Ayush system of medicine for the prevention or treatment of ailments during the last 365 days, compared with 46.3% in rural areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BF4AVQd
via IFTTT

Read More

Suven Pharma to acquire controlling stake in Hyderabad-based CDMO Sapala Organic

Suven will initially acquire a 67.5% equity stake of Sapala subject to customary working capital and net debt adjustments, the remaining stake a few months after FY2026-27, as per the terms of the definitive agreements, the company told stock exchanges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ptfAvkq
via IFTTT

Read More

USFDA issues Form 483 with five observations to Torrent Pharma unit

Torrent Pharmaceuticals announced that the US Food and Drug Administration (USFDA) issued a Form 483 with five observations after inspecting its manufacturing plant in Indrad, Gujarat, from June 3 to June 12. The inspection included a pre-approval inspection (PAI) and a Good Manufacturing Practice (GMP) inspection. The company stated that there were no observations related to data integrity. Torrent Pharma plans to respond to the USFDA within the prescribed time frame and work closely with the agency to address the observations promptly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HaxT8sz
via IFTTT

Read More

Dr Reddy's signs in-licensing pact with Ingenus Pharmaceuticals for cancer treatment injection

Dr Reddy's Laboratories Ltd has signed a licensing agreement with US-based Ingenus Pharmaceuticals to commercialize Cyclophosphamide injection for cancer treatment. Dr Reddy's USA will commercialize the injection in the US market, paying Ingenus 50% of the calculated profit share.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/w6SFzTY
via IFTTT

Read More

Glenmark gets USFDA nod to market generic drug

Glenmark Pharmaceuticals announced that it has received USFDA approval to market its generic Esomeprazole Magnesium delayed-release capsules, used to treat excess stomach acid conditions. This generic version of Haleon US Holdings LLC's Nexium is expected to compete in a market where Nexium24 HR 20 mg capsules have annual sales of approximately $259.2 million

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0WOFqe7
via IFTTT

Read More

Kotak Alt funds Matrix founder's buyout of Viatris API business

Kotak Alternate Asset Managers has announced a Rs 1,445 crore investment in the acquisition of Viatris' active pharmaceutical ingredient (API) business by Matrix Laboratories founder Nimmagadda Prasad. The investment was made through Kotak Strategic Situations Fund II, as stated in a news release on Tuesday. However, specific details regarding the funding structure were not disclosed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F9jBGrh
via IFTTT

Read More

Kotak Alternate Asset Managers invests Rs 1,445 cr to help Matrix Pharma execute acquisition

Kotak Alternate Asset Managers Ltd invested Rs 1,445 crore in Matrix Pharma for acquiring Vaitris' API business, making Matrix the 2nd largest Indian API player with global leadership in ARV APIs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/09B7xLN
via IFTTT

Read More

Viagra may improve brain functions, prevent dementia: Oxford Study

Sildenafil, known as Viagra, may help prevent memory-related problems by improving cerebral blood flow and blood vessel function, reducing the risk of vascular dementia. A University of Oxford study, highlighted by Dr. Praveen Gupta and Dr. Manjari Tripathi, shows promise but requires further research. Vascular dementia, affecting 40% of India's 5.3 million dementia patients, differs from Alzheimer's disease.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YmAgQaM
via IFTTT

Read More

SII, the world’s largest vaccine maker, sees demand doubling in five years

Serum Institute of India Pvt. is gearing up to meet the growing demand for life-saving vaccines, with expectations to double sales in the next five years. The world's largest vaccine maker, based in Pune, currently has the capacity to produce 3 billion doses annually but only sells about half of that. CEO Adar Poonawalla is optimistic about the increasing uptake of vaccines globally as countries boost their healthcare budgets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7FvfpM8
via IFTTT

Read More

CX Partners buys controlling stake in fertility centre Sabine

Founded in 2010, Sabine's Muvattupuzha hospital draws couples from across Kerala for IVF treatment that helps individuals or couples get pregnant. On an average, Sabine does about 500-600 IVF cycles per month, or about 42%-45% of all IVF procedures in Kerala.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f4LqPxe
via IFTTT

Read More

Mankind Pharma in race with PEs to buy BSV Group at possible valuation of Rs 13,000 crore

Warburg Pincus, ChrysCapital, TPG, Blackstone, EQT, Mankind Pharma, and Dr Reddy's Laboratories are competing to acquire BSV Group, a biopharma firm specializing in women's health and critical care products, indicating a trend of consolidation in the domestic pharma sector. Mankind, Dr. Reddy’s, and Blackstone have evaluated BSV at different times, including before Advent's acquisition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rn9v0ef
via IFTTT

Read More

Pharma industry raises concerns over new Schedule M's impact on cosmetic manufacturing

The pharmaceutical industry, represented by the Federation of Pharma Enterprises (FoPE), has expressed concerns over the government's new Schedule M, which prohibits the manufacture of any product other than drugs in units licensed for drug production. FoPE argues that setting up a separate plant for cosmetic manufacturing is financially unviable for medium and small-scale enterprises. They are requesting permission to manufacture cosmetics in the area designated for topical products like creams and lotions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LVCr1eR
via IFTTT

Read More

Mankind Pharma scouts for M&A deals to boost local branded biz

Mankind Pharma, the fourth-largest pharmaceutical company in India, led by Rajeev Juneja, is seeking mergers, acquisitions, and in-licensing deals to enhance its branded formulation business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EC2GWlq
via IFTTT

Read More

CDSCO panel gives nod for continuation of phase-II clinical trial of SII's dengue vaccine

An expert committee recommended continuation of phase-II clinical trial of Serum Institute of India's vaccine against dengue after successful phase-I interim trial in Australia. The SEC recommendations were made on May 31.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AavbBMz
via IFTTT

Read More

Indoco Remedies gets USFDA nod to market generic diabetes drug

Indoco Remedies on Thursday said it has received approval from the US health regulator to market a generic diabetes medication. The company has received tentative approval from the US Food and Drug Administration (USFDA) for abbreviated new drug application (ANDA) for Canagliflozin and Metformin Hydrochloride tablets in various strengths, Indoco Remedies said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wHbSIzu
via IFTTT

Read More

Human death from bird flu: What is bird flu? Signs, treatments, precautions

A 59-year-old man in Mexico City who contracted a subtype of bird flu has died in Mexico City, the World Health Organization said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WSf8vw0
via IFTTT

Read More

Torrent Pharma inks licensing pact with Takeda to commercialise GERD drug

Torrent Pharmaceuticals on Wednesday said it has entered a non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan in India. Vonoprozan is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of acid related disorders gastroesophageal reflux disease.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/efJ1RhC
via IFTTT

Read More

Govt issues guidance paper to strengthen vaccine companies' reporting of adverse events

The new report released last week aims to provide guidance to the manufacturers and importers of vaccines in the country so as to strengthen their AE/AEFI (adverse events following immunisation) monitoring and reporting and pharmacovigilance department to ensure patient safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RQ5dJZD
via IFTTT

Read More

Organon appoints Vivek Soares as country lead for India, South Asia

US-based healthcare firm Organon announced Vivek Soares as the new country lead for India and South Asia, bringing over 20 years of biopharmaceutical experience. Soares, previously with Organon Thailand, will succeed Anjan Sen, pivotal in establishing Organon's India operations. Soares aims to drive growth in the region, working towards a healthier future for women.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Dxb9LAs
via IFTTT

Read More

US-based Zeda plans to raise up to $200 million for India foray

US-based Zeda Holdings plans to raise $200 million for its India expansion, led by CEO Shri Shetty. The company uses 3D printing for orthopaedic implants.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EuYBn79
via IFTTT

Read More

GSK blood cancer drug nearly halves risk of death in late-stage trial

In the trial of 302 patients with relapsed or difficult-to-treat multiple myeloma, 71% of those who received Blenrep in combination with the steroid dexamethasone and pomalidomide were alive without their disease worsening at the end of a year. That compared with progression-free survival (PFS) of 51% of those who were treated with pomalidomide, dexamethasone and bortezomib. Pomalidomide is a generic version of Bristol Myers Squibb's Pomalyst, while bortezomib is the generic of Takeda Pharmaceuticals' Velcade.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NCa30OH
via IFTTT

Read More

Sun Pharma expects high single-digit top line growth in current fiscal

Sun Pharmaceutical Industries expects high single-digit top line growth in FY24 with total revenue at Rs 48,497 crore, led by Managing Director Dilip Shanghvi. The firm anticipates similar growth in FY25 with investments in product launches and R&D activities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dmnTsGo
via IFTTT

Read More